As biotechs face increasingly tight development timelines, scale-up headaches and, more recently, unpredictable policy fluctuations, one way to stand out as a CDMO partner is picking a specialty an | ...
Among the measures ImmunityBio has implemented are “expanded promotional review protocols,” executive training and external ...
Neurocrine Biosciences, forever a possible M&A target in the biopharma industry, is making a major acquisition itself. | ...
A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...
The doctors at fictional Sacred Heart Hospital are in, and so is Insulet’s real-life wearable insulin management system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results